Dramatic success has been demonstrated in treating certain advanced metastatic cancers using immunotherapy. Yet, patients who respond represent a minority of cases. The discovery of new predictive biomarkers is critical to improving our ability to (1) predict whether a patient is likely to respond to available drugs and (2) guide treatment decisions. Platforms that can elucidate the spatial relationship between immune system cells and the tumor are critical to this endeavor. Recent advances in multiplex immunofluorescence (mIF) have made it possible to map the tumor microenvironment across an entire tissue section mounted on a microscope slide with single-cell resolution. An innovative approach has been developed to analyze large mIF datasets using celestial object–mapping algorithms to rapidly identify optimized predictive phenotypic signatures. This interdisciplinary platform, called AstroPath, makes use of immunology, pathology, computer science, and astronomy to lay the foundation for rapid, efficient biomarker discovery.
During the webinar, the speakers will:
- Describe how the AstroPath technology was conceived and developed
- Share examples of successes applying AstroPath to answering questions about interactions
- between the tumor microenvironment and the immune system
- Provide preliminary results of comparisons across different institutions to assess mIF assay performance
- Answer your questions live during the broadcast.
This webinar will last for approximately 60 minutes.